282 related articles for article (PubMed ID: 23291936)
1. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.
Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Chang SY; Chang SC
Hum Vaccin Immunother; 2013 Feb; 9(2):398-404. PubMed ID: 23291936
[TBL] [Abstract][Full Text] [Related]
2. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients.
Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Hsiao CF; Tseng YT; Su YC; Chang SF; Chang SY; Chang SC
Vaccine; 2012 May; 30(24):3526-33. PubMed ID: 22484349
[TBL] [Abstract][Full Text] [Related]
3. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.
Hung CC; Chang SY; Su CT; Chen YY; Chang SF; Yang CY; Liu WC; Wu CH; Chang SC
HIV Med; 2010 Jan; 11(1):54-63. PubMed ID: 19659943
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults.
Crum-Cianflone NF; Huppler Hullsiek K; Roediger M; Ganesan A; Patel S; Landrum ML; Weintrob A; Agan BK; Medina S; Rahkola J; Hale BR; Janoff EN;
J Infect Dis; 2010 Oct; 202(7):1114-25. PubMed ID: 20795819
[TBL] [Abstract][Full Text] [Related]
5. Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy.
Lu CL; Chang SY; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Hung CC
Vaccine; 2014 Feb; 32(9):1031-5. PubMed ID: 24440112
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
[TBL] [Abstract][Full Text] [Related]
7. Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults.
Rossheim AE; Young AM; Siik J; Cunningham TD; Troy SB
Hum Vaccin Immunother; 2016 Aug; 12(8):2117-2123. PubMed ID: 27172241
[TBL] [Abstract][Full Text] [Related]
8. Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.
Abzug MJ; Song LY; Levin MJ; Nachman SA; Borkowsky W; Pelton SI;
Vaccine; 2013 Oct; 31(42):4782-90. PubMed ID: 23954381
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
[TBL] [Abstract][Full Text] [Related]
10. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.
Lee KY; Tsai MS; Kuo KC; Tsai JC; Sun HY; Cheng AC; Chang SY; Lee CH; Hung CC
Hum Vaccin Immunother; 2014; 10(12):3700-10. PubMed ID: 25483681
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants.
Madhi SA; Izu A; Violari A; Cotton MF; Panchia R; Dobbels E; Sewraj P; van Niekerk N; Jean-Philippe P; Adrian PV;
Vaccine; 2013 Jan; 31(5):777-83. PubMed ID: 23228814
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.
King JC; Vink PE; Farley JJ; Parks M; Smilie M; Madore D; Lichenstein R; Malinoski F
Pediatr Infect Dis J; 1996 Mar; 15(3):192-6. PubMed ID: 8852905
[TBL] [Abstract][Full Text] [Related]
13. Single-Dose 13-Valent Conjugate Pneumococcal Vaccine in People Living With HIV - Immunological Response and Protection.
Romaru J; Bahuaud M; Lejeune G; Hentzien M; Berger JL; Robbins A; Lebrun D; N'Guyen Y; Bani-Sadr F; Batteux F; Servettaz A
Front Immunol; 2021; 12():791147. PubMed ID: 34987514
[TBL] [Abstract][Full Text] [Related]
14. Alterations in serotype-specific B cell responses to the 13-valent pneumococcal conjugate vaccine in aging HIV-infected adults.
Ohtola JA; Khaskhely NM; Saul-Mcbeth JL; Iyer AS; Leggat DJ; Khuder SA; Westerink MAJ
Vaccine; 2016 Jan; 34(4):451-457. PubMed ID: 26707220
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
[TBL] [Abstract][Full Text] [Related]
16. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.
Schaballie H; Wuyts G; Dillaerts D; Frans G; Moens L; Proesmans M; Vermeulen F; De Boeck K; Meyts I; Bossuyt X
Clin Exp Immunol; 2016 Aug; 185(2):180-9. PubMed ID: 26939935
[TBL] [Abstract][Full Text] [Related]
17. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults.
Lesprit P; Pédrono G; Molina JM; Goujard C; Girard PM; Sarrazin N; Katlama C; Yéni P; Morineau P; Delfraissy JF; Chêne G; Lévy Y;
AIDS; 2007 Nov; 21(18):2425-34. PubMed ID: 18025879
[TBL] [Abstract][Full Text] [Related]
18. Effect of Maternal Immunization With 10-Valent Pneumococcus Conjugate Vaccine (PCV-10), 23-Valent Pneumococcus Polysaccharide Vaccine, or Placebo on the Immunogenicity of PCV-10 in Human Immunodeficiency Virus-Exposed Uninfected Infants: A Randomized Clinical Trial.
Mussi-Pinhata MM; Ward S; Laimon L; Pelton SI; Canniff J; Golner A; Bone F; Newton L; Muresan P; Fenton T; Johnson MJ; João EC; Santos BR; Pilotto JH; Oliveira RH; Pinto JA; Dal Bó AGBL; Kreitchmann R; Chakhtoura N; Duarte G; Weinberg A
Clin Infect Dis; 2022 Sep; 75(6):996-1005. PubMed ID: 35037049
[TBL] [Abstract][Full Text] [Related]
19. Safety, immunogenicity, and transplacental antibody transport of conjugated and polysaccharide pneumococcal vaccines administered to pregnant women with HIV: a multicentre randomised controlled trial.
Weinberg A; Muresan P; Laimon L; Pelton SI; Goldblatt D; Canniff J; Zimmer B; Bone F; Newton L; Fenton T; Kiely J; Johnson MJ; Joao EC; Santos BR; Machado ES; Pinto JA; Chakhtoura N; Duarte G; Mussi-Pinhata MM;
Lancet HIV; 2021 Jul; 8(7):e408-e419. PubMed ID: 33915104
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults in the era of highly active antiretroviral therapy: analysis stratified by CD4 T-cell count.
Song JY; Cheong HJ; Noh JY; Choi MJ; Yoon JG; Kim WJ
Hum Vaccin Immunother; 2020; 16(1):169-175. PubMed ID: 31441710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
